Evaluation of the release rate of bioactive recombinant human epidermal growth factor from crosslinking collagen sponges.
The purpose of this study was to prepare recombinant human epidermal growth factor (rhEGF) collagen sponges for topical applications and investigate the effects of different types of crosslinked collagen sponges as platforms for the controlled release of rhEGF. The microstructure and the drug release rates of collagen sponges were modified through treatment with different types (glutaraldehyde (GTA), genipin and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC)), different concentrations of crosslinking agents and various preparation conditions. A controlled release profile was observed for the crosslinked collagen sponges as compared to the non-crosslinked ones. The results indicated that the GTA crosslinked sponges have the most potent controlling effect. As the amount of GTA increased, a greater rigidity of the collagen sponge structure combined with a lower hydrophilicity was observed, leading to a decreased drug release rate and an increased water uptake. This study also demonstrated that a good correlation was obtained for in vitro release rates of rhEGF using the power model. The crosslinked rhEGF collagen sponges showed a successful delivery of rhEGF in bioactive form to stimulate cell proliferation.